Cargando…
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
BACKGROUND: A phase I trial was performed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics and immunogenicity of the anti-EpCAM immunotoxin (IT) MOC31PE in cancer patients. An important part of the study was to investigate whether the addition of Sandimmune (cyclosporin, CsA)...
Autores principales: | Andersson, Y, Engebraaten, O, Juell, S, Aamdal, S, Brunsvig, P, Fodstad, Ø, Dueland, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705890/ https://www.ncbi.nlm.nih.gov/pubmed/26554649 http://dx.doi.org/10.1038/bjc.2015.380 |
Ejemplares similares
-
Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Thorgersen, Ebbe Billmann, et al.
Publicado: (2021) -
MOC31PE immunotoxin – targeting peritoneal metastasis from epithelial ovarian cancer
por: Andersson, Yvonne, et al.
Publicado: (2017) -
The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
por: Wiiger, Merete Thune, et al.
Publicado: (2014) -
Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009) -
Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM
por: Lv, Minghua, et al.
Publicado: (2015)